GenScript Biotech Announces 2023 Annual Results with a Five-Year CAGR stands at 30%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
JPMorgan on Legend Biotech Corp. (LEGN): 'Remain Confident in Carvykti’s Profile Post ODAC Briefing Docs'
March 13, 2024 12:10 PM EDTJPMorgan analyst Jessica Fye reiterated an Overweight rating on Legend Biotech Corp. (NASDAQ: LEGN).
The analyst comments "While we expect the FDAs question around the imbalance in early death in CARTITUDE-4 to be taken seriously at Fridays ad com on Carvykti, the data around early deaths show it... More
